Stocks Health care PRCT
NASDAQ · Health carePROCEPT BioRobotics Corp (PRCT)
PROCEPT BioRobotics Corp brought in $352.3M of revenue over the twelve months to September 30, 2026, up 17.5% from a year earlier. It posted a net loss of $114.9M. In fiscal 2025 capital spending exceeded operating cash flow by $58.3M. At September 30, 2026 it held $218.4M in cash against $51.8M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about PROCEPT BioRobotics Corp
- Net worth
- PROCEPT BioRobotics Corp has a market value (market cap) of $1.3B at the latest share price, and shareholders' equity of $328.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $308.1M (+37.2% year on year), with a net loss of $95.6M. Over the 12 months to September 30, 2026: revenue $352.3M, net loss $114.9M.
- Cash flow
- In fiscal 2025 operations used $49M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- PROCEPT BioRobotics Corp's next report is expected around February 24, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What PROCEPT BioRobotics Corp does
PROCEPT BioRobotics Corp is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker PRCT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $308.1M | -$95.6M | -$1.72 | -$58.3M |
| 2024 | $224.5M | -$91.4M | -$1.75 | -$103.6M |
| 2023 | $136.2M | -$105.9M | -$2.24 | -$133.2M |
| 2022 | $75M | -$87.2M | -$1.96 | -$83M |
| 2021 | $34.5M | -$59.9M | -$3.63 | -$57.9M |
| 2021 | $7.7M | -$53M | -$14.47 | -$48.6M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where PRCT ranks in Health care
Latest SEC filings
What PROCEPT BioRobotics Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 4, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 18% to $98.3M versus the same quarter last year; diluted EPS -$0.46 versus -$0.38.
- November 4, 2026
- October 30, 2026Passive stake changed SCHEDULE 13G/A
- October 2, 2026Executive or director change8-KPROCEPT BioRobotics expanded its board of directors to ten members and appointed Dr. Michael Mack as an independent director.
- September 24, 2026Material agreement8-KPROCEPT BioRobotics extended the maturity date of its term loan with CIBC by 12 months.
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 19% to $94.5M versus the same quarter last year; diluted EPS -$0.47 versus -$0.35.
- August 4, 2026
- July 29, 2026Passive stake changed SCHEDULE 13G/A
- June 10, 2026
- June 1, 2026
Insider trades
What the people running PROCEPT BioRobotics Corp did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $114.7K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 6, 2026 | Sharma PoojaChief Strat/Marketing Officer | Sold | 4,710 | $92.9K |
| October 2, 2026 | Mack MichaelDirector | Received as pay | 7,727 | - |
| September 9, 2026 | Templin Barry LEVP, Chief Technology Officer | Sold | 373 | $7.8K |
| September 9, 2026 | Nouri AlalehEVP, CLO, CORP. SEC. | Sold | 297 | $6.2K |
| September 9, 2026 | Waters KevinEVP, CFO | Sold | 373 | $7.8K |
| August 13, 2026 | Sharma PoojaChief Strat/Marketing Officer | Received as pay | 23,622 | - |
| August 13, 2026 | Waters KevinEVP, CFO | Received as pay | 29,527 | - |
| August 13, 2026 | Templin Barry LEVP, Chief Technology Officer | Received as pay | 26,246 | - |
Who owns PRCT
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| T. Rowe Price Investment Management, Inc.13G, passive | 5.9% | February 17, 2026 |
| BNP Paribas Asset Management Holding S.A.13G, passive | 5.5% | February 11, 2026 |
| Vanguard Capital Management13G, passive | 5% | April 30, 2026 |
Largest institutional holders
Insiders
14 insiders reported holding 2,348,607 shares in total, about $53.8M at the last price.
| Holder | Shares |
|---|---|
| Moll Frederic HDirector | 866,474 |
| Desai Antal RohitDirector | 464,729426,262 held indirectly |
| Wood Larry LPresident, CEO, Director | 337,27823,900 held indirectly |
| Waters KevinEVP, CFO | 180,355 |
| Nouri AlalehEVP, CLO, CORP. SEC. | 127,737 |
| Sharma PoojaChief Strat/Marketing Officer | 106,471 |
| Harris Taylor C.Director | 102,491 |
| Templin Barry LEVP, Chief Technology Officer | 94,826 |
| Garrett MaryDirector | 17,700 |
| Little Elisabeth SandovalDirector | 15,876 |
Questions about PRCT
What does PROCEPT BioRobotics Corp do?
PROCEPT BioRobotics Corp is a company in the Health care sector, listed on NASDAQ as PRCT. Its shares trade on NASDAQ under the ticker PRCT.
What is PROCEPT BioRobotics Corp's net worth?
PROCEPT BioRobotics Corp has a market value (market cap) of $1.3B at the latest share price, and shareholders' equity of $328.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is PROCEPT BioRobotics Corp profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $114.9M on revenue of $352.3M.
How much revenue does PROCEPT BioRobotics Corp make?
Over the twelve months to September 30, 2026 PROCEPT BioRobotics Corp reported revenue of $352.3M. That is 17.5% more than a year earlier.
When did PROCEPT BioRobotics Corp last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the insider trade from November 6, 2026.
When is PROCEPT BioRobotics Corp's next earnings report?
PROCEPT BioRobotics Corp's next report is expected around February 24, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare PRCT with
Follow PRCT
Get an email when PROCEPT BioRobotics Corp files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values PROCEPT BioRobotics Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.